Tango Therapeutics, Inc. (TNGX)
NASDAQ: TNGX · Real-Time Price · USD
3.100
+0.160 (5.44%)
Dec 20, 2024, 4:00 PM EST - Market closed
Tango Therapeutics Revenue
Tango Therapeutics had revenue of $11.61M in the quarter ending September 30, 2024, with 8.15% growth. This brings the company's revenue in the last twelve months to $43.38M, up 15.67% year-over-year. In the year 2023, Tango Therapeutics had annual revenue of $36.53M with 46.93% growth.
Revenue (ttm)
$43.38M
Revenue Growth
+15.67%
P/S Ratio
7.71
Revenue / Employee
$309,879
Employees
140
Market Cap
333.00M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 36.53M | 11.67M | 46.93% |
Dec 31, 2022 | 24.86M | -12.18M | -32.89% |
Dec 31, 2021 | 37.04M | 29.39M | 383.83% |
Dec 31, 2020 | 7.66M | -16.99M | -68.94% |
Dec 31, 2019 | 24.65M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Revance Therapeutics | 256.95M |
Valneva SE | 176.82M |
Kamada | 158.38M |
Sage Therapeutics | 106.40M |
NeuroPace | 76.45M |
Aquestive Therapeutics | 58.90M |
Eton Pharmaceuticals | 34.68M |
Silence Therapeutics | 21.77M |
TNGX News
- 18 days ago - Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 24 days ago - Tango Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference - Business Wire
- 6 weeks ago - Tango Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights - Business Wire
- 6 weeks ago - Tango Therapeutics Reports Positive TNG462 Clinical Data and Provides Update on PRMT5 Development Program - Business Wire
- 3 months ago - Tango Therapeutics: Amgen Missteps Devalue PRMT5 Candidates Ahead Of Critical Data - Seeking Alpha
- 4 months ago - Tango Therapeutics to Participate in Upcoming Investor Conferences - Business Wire
- 4 months ago - Tango Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Highlights - Business Wire
- 7 months ago - Tango Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference - Business Wire